Adoram Therapeutics
About Adoram Therapeutics
The startup develops allosteric modulators that target adenosine pathways in solid tumors, enhancing the efficacy of small molecule immunotherapy. This approach addresses the limitations of existing treatments in adenosine-rich environments, providing researchers with a viable option to meet critical needs in onco-immunology.
What does Adoram Therapeutics do?
The startup develops allosteric modulators that target adenosine pathways in solid tumors, enhancing the efficacy of small molecule immunotherapy. This approach addresses the limitations of existing treatments in adenosine-rich environments, providing researchers with a viable option to meet critical needs in onco-immunology.
Where is Adoram Therapeutics located?
Adoram Therapeutics is based in Lancy, Schweiz/Suisse/Svizzera/Svizra.
When was Adoram Therapeutics founded?
Adoram Therapeutics was founded in 2022.
How much funding has Adoram Therapeutics raised?
Adoram Therapeutics has raised 10000.
Who founded Adoram Therapeutics?
Adoram Therapeutics was founded by Hesham Ismail HAMED and David Pejoski.
- Hesham Ismail HAMED - Co-CEO/CSO
- David Pejoski - Co-founder/Co-CEO/COO/Board Member
- Location
- Lancy, Schweiz/Suisse/Svizzera/Svizra
- Founded
- 2022
- Funding
- 10000
- Employees
- 3 employees
- Major Investors
- FONGIT Innovation Fund